Table 1 Prevalence of autoreactivity in patients with atopic dermatitis categorized by age
Patients with atopic dermatitis | Severity of AD/population | Prevalence of IgE autoreactivity in AD | Prevalence of IgE autoreactivity in control subjects | References |
|---|---|---|---|---|
Children 0–1 year | Mild–severe | 20.0% (1/5) | / | Natter et al. [19] |
Moderate–severe | 15.0% (25/60) | / | Mothes et al. [20] | |
Children 2–13 years | Mild–severe | 16.7% (1/6) | / | Natter et al. [19] |
Moderate–severe | 80.0% (16/20) | / | Mothes et al. [20] | |
Adolescents 14–23 years | Mild–severe | 63.6% (7/11) | / | Natter et al. [19] |
EASI: 10–39.4 | 50.0% (2/4) | / | Mitterman et al. [38] | |
Adults ≥ 24 years | / | 60.0% (12/20) | 0.0% (0/2) | Valenta et al. [17] |
Mild–severe | 44.8% (13/29) | / | Natter et al. [19] | |
/ | 62.5% (10/16) | 0% (0/1) | Ochs et al. [57] | |
/ | 2.5% (1/40) SART2161 | 4.9% (2/41) SART2161 | Kawamoto et al. [30] | |
/ | 37.5% (15/40) SART109 | 29.3% (12/41) SART109 | Â | |
/ | 15% (6/40) SART315 | 17.1% (7/41) SART315 | Â | |
/ | 27.5% (11/40) CypB84 | 29.3% (12/41) CypB84 | Â | |
/ | 17.5% (7/40) CypB91 | 31.7% (13/41) CypB91 | Â | |
/ | 10% (4/40) ART475 | 12.2% (5/41) ART475 | Kinaciyan et al. [53] | |
Mild | 100.0% (1/1) | / | Kortekangas-Savolainen [33] | |
/ | 37.0% (10/27) | / | Aichberger et al. [37] | |
/ | 91.7% (11/12) | 0.0% (0/6) | Mothes et al. [20] | |
/ | 23.0% (40/174) | / | Schmid-Grendelmeier et al. [34] | |
EASI: 0.6–39.4 | 42.0% (29/69) | / | Tanaka et al. [55] | |
Mild–severe | 77.0% (47/61) | 8.7% (4/46) | Mitterman et al. [38] | |
EASI: 4.4–59.8 | 85.7% (6/7) | 0.0% (0/12) | Altrichter et al. [35] | |
EASI: 0.6–39.4 | 28.0% (54/192) | / | Zeller et al. [36] | |
SCORAD: 21.93–71.36 | 71.8% (51/71) | 0.0% (0/36) | Watanabe et al. [31] | |
/ | 14.8% (9/61) | / | Aichberger et al. [37] | |
/ | 91.7% (11/12) | 0.0% (0/6) | Lucae et al. [91] | |
Moderate–severe | 100% (4/4) | / | Roesner et al. [106] | |
/ | 91.7% (11/12) | / | Â |